Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

Davis, John C.; Heijde, Désirée M van der; Braun, J.; Dougados, Maxime; Cush, John J.; Clegg, Daniel O.; Inman, Robert D.; Kivitz, Alan; Zhou, Lifen; Solinger, Alan M.; Tsuji, W.

doi:10.1136/ard.2004.035105

Cited by 163 publications

(90 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the etanercept trial for AS patients, several cases of uveitis/iritis (some with prior history, others with new diagnosis) as well as de novo colitis and psoriasis were reported [25]. In the study comparing adalimumab, infliximab, and etanercept in the treatment of uveitis in SpA patients, etanercept did not decrease the rate of uveitis flares in patients with at least one prior flare; the monoclonal anti-TNF antibodies did decrease the rate of uveitis flares [28].…”

Section: Skin Reactions and Extra-articular Featuresmentioning

confidence: 99%

See 1 more Smart Citation

Differential Adverse Events Between TNF-α Inhibitors and IL-17 Axis Inhibitors for the Treatment of Spondyloarthritis

Antonelli

Khan

Magrey

2015

Curr Treat Options in Rheum

View full text Add to dashboard Cite

Section: Skin Reactions and Extra-articular Featuresmentioning

confidence: 99%

“…This was noted to be transient and resolved with continued therapy [24]. Cytopenias have been reported in TNF-inhibitor trials, including thrombocytopenia, lymphocytopenia, and neutropenia [25,26]. These cytopenias are generally mild and transient.…”

Section: Laboratory Abnormalitiesmentioning

confidence: 99%

Differential Adverse Events Between TNF-α Inhibitors and IL-17 Axis Inhibitors for the Treatment of Spondyloarthritis

Antonelli

Khan

Magrey

2015

Curr Treat Options in Rheum

View full text Add to dashboard Cite

“…A major outcome of this study is the discovery that administration of TNF-aR-Fc, a relatively safe TNF-a inhibitor that is widely used in the treatment of inflammatory diseases, could have an antitumor effect by enhancing immunosurveillance (23,24). This finding, as well as others, support the idea that TNF-a can have protumor activity and, thus, the treatment of tumors via TNF-a blockade is a reasonable approach to the treatment of tumors (25).…”

Section: Discussionmentioning

confidence: 99%

Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor-α2

et al. 2008

View full text Add to dashboard Cite

In previous studies, we described a''counter-immunosurveillance'' mechanism initiated by tumor-activated, interleukin-13 (IL-13)-producing natural killer T cells that signal Gr-1 + cells to produce transforming growth factor-B 1 (TGF-B 1 ), a cytokine that suppresses the activity of tumor-inhibiting cytolytic CD8 + T cells. Here, we show that in two tumor models (the CT-26 metastatic colon cancer and the 15-12RM fibrosarcoma regressor models), this counter-surveillance mechanism requires the expression of a novel IL-13 receptor, IL-13RA 2 , on Gr-1 intermediate cells, because downregulation of IL-13RA 2 expression or the activator protein-1 signal generated by the receptor via in vivo administration of specific small interfering RNA or decoy oligonucleotides leads to loss of TGF-B 1 production. Furthermore, acting on prior studies showing that IL-13RA 2 expression is induced (in part) by tumor necrosis factor-A (TNF-A), we show that receptor expression and TGF-B 1 production is inhibited by administration of a TNF-A-neutralizing substance, TNF-ARFc (etanercept). Taking advantage of this latter fact, we then show in the CT-26 model that counter-immunosurveillance can be inhibited, anti-CT-26-specific CD8 + cytolytic activity can be restored, and CT-26 metastatic tumor nodules can be greatly decreased by administration of TNF-AR-Fc. Corroborative data were obtained using the 15-12RM fibrosarcoma model. These studies point to the prevention of metastatic cancer with an available agent with already known clinically acceptable adverse effects and toxicity. [Cancer Res 2008;68(9):3467-75]

show abstract

“…In a later published open label extension of the 2003 study, Davis et al 45 demonstrated sustained effi cacy of etanercept at 96 weeks with 74% of 128 of the original etanercept treated patients achieving ASAS20 at 96 weeks. In the earlier placebo group, ASAS20 was met by 70% of the 129 patients at 24 weeks and 78% at 72 weeks.…”

Section: Asas Response Criteria 52mentioning

confidence: 99%

The Treatment of Ankylosing Spondylitis and Psoriatic Arthritis with Etanercept: A Comprehensive Review

Collamer

Battafarano

2009

Clinical Medicine. Therapeutics

View full text Add to dashboard Cite

Etanercept is a dimeric recombinant soluble tumor necrosis factor (TNF) receptor protein utilized in the treatment of various infl ammatory diseases, including ankylosing spondylitis and psoriatic arthritis. Etanercept binds the proinfl ammatory cytokine TNF and blocks its interaction with soluble TNF receptors, thus decreasing the infl ammatory response. Several randomized controlled clinical trials have demonstrated the effi cacy, safety and tolerability of etanercept in the treatment of both ankylosing spondylitis and psoriatic arthritis. These trials have also shown signifi cant reductions in markers of systemic infl ammation and improvements in patient-reported quality of life measures. Inhibition of radiographic progression has been established in etanercept-treated psoriatic arthritis patients, and ankylosing spondylitis patients have demonstrated decreases in bony infl ammation; however, current data does not support a reduction in bone proliferation in ankylosing spondylitis patients. Concerns regarding long-term toxicity, effi cacy, and cost-effectiveness considerations persist and guidelines have been published to assist the clinician with appropriate patient selection for this biologic therapy. Current data indicates etanercept therapy has been a very successful and well-tolerated therapy for numerous ankylosing spondylitis and psoriatic arthritis patients and will likely continue to be a cornerstone therapy for treatment of these challenging diseases in the foreseeable future.

show abstract

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

Cited by 163 publications

References 16 publications

Differential Adverse Events Between TNF-α Inhibitors and IL-17 Axis Inhibitors for the Treatment of Spondyloarthritis

Differential Adverse Events Between TNF-α Inhibitors and IL-17 Axis Inhibitors for the Treatment of Spondyloarthritis

Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor-α2

The Treatment of Ankylosing Spondylitis and Psoriatic Arthritis with Etanercept: A Comprehensive Review

Contact Info

Product

Resources

About